Navigation Links
arGEN-X Receives Two Preclinical Milestone Payments Under Collaboration With Shire
Date:1/13/2014

BREDA, The Netherlands and GHENT, Belgium, January 13, 2014 /PRNewswire/ --

Enters into pilot research agreement with Boehringer Ingelheim

arGEN-X, a clinical stage human therapeutic antibody company, announces the attainment of two important success milestones in its SIMPLE Antibody™ research and product development collaboration with Shire. The milestones, which trigger undisclosed payments from Shire, relate to demonstration of in vivo proof of concept for one of the ongoing antibody discovery programs.

Initiated in February 2012, the collaboration is focused on creating human therapeutic antibodies against complex targets implicated in severe, rare genetic diseases. Shire has an option to license the most promising antibody leads for further development and commercialization worldwide, in return for fee, milestone and royalty payments.

"Yet again the functional diversity of SIMPLE Antibodies™ has enabled our scientists to set a precedent in validating highly complex targets both in vitro and in vivo and identifying antibody leads with exciting therapeutic potential," said Hans de Haard, PhD, Chief Scientific Officer of arGEN-X. "We value our collaboration with Shire very highly and continue to make excellent progress through the outstanding joint efforts of our teams."

"We are very impressed by the productivity and consistent success of our therapeutic antibody collaboration with arGEN-X," said  Albert Seymour, Head of Discovery Biology and Translational Research at Shire.

arGEN-X today also announced the initiation of a new pilot research agreement with Boehringer Ingelheim. No further details are being disclosed at this stage.

About arGEN-X

arGEN-X is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody tec
'/>"/>

SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
2. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
3. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
4. arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer
5. arGEN-X raises EUR 5 Million from PMV in Extension of EUR 32.5 Million Series B
6. arGEN-X Starts Phase Ib Expansion Cohorts With ARGX-110, a Novel Anti-CD70 Antibody, in Cancer Patients
7. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
8. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
9. Nephros Receives 510(k) Clearance for Hemodiafiltration System
10. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
11. BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... QPID Health , a leader in clinical intelligence software, today ... and their first West Coast location in San ... in Boston , and will house product development, ... Southern California office will be located at 1000 ... demands of customers nationwide.  Both new locations will be operational ...
(Date:9/16/2014)... , Sept. 16, 2014 Surgeons at ... describe in a case report the first successful use ... a 13- year-old boy with failing Fontan circulation to ... he was 3 years old, the patient received a ... as functional single ventricle. "The Fontan operation is the ...
(Date:9/16/2014)... Research and Markets has ... Devices Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth ... laparoscopic devices. The report provides a ... applications and industry chain structure. The laparoscopic devices ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3Global Laparoscopy Devices Industry Report 2014 2
... 23, 2011 The U.S. Food and Drug Administration ... active ulcerative colitis (UC) in children older than 6 ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... induces and maintains clinical remission in these patients. ...
... ANN ARBOR, Mich., Sept. 23, 2011 Adapting adult medical ... often problematic practice across U.S. hospitals. At the ... and researchers who care for children have been leading the ... test medical devices and curb problems that come from using ...
Cached Medicine Technology:FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years 2FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years 3University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 2University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 3University of Michigan Pediatric Device Inventors Awarded Funds to Design Child-Specific Medical Devices 4
(Date:9/16/2014)... Centre, NY (PRWEB) September 16, 2014 ... product manufactured by Johnson & Johnson subsidiary Ethicon concluded ... of plaintiff Jo Huskey and awarding her $3.27 million ... According to the Reuters report, “jurors found Ethicon liable ... and their doctors that users were at risk from ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. ... as one of the Top Doctors of 2014. The ... metropolitan magazine serving the Houston area. They award esteemed ... their outstanding services. This accomplishment will be included in ... — a special publication listing all the winners of ...
(Date:9/16/2014)... September 16, 2014 Duke’s Chowder House ... Rebls and Gratafy for a fun evening ... hub is firmly cemented. With the growth of companies in these ... for people who work in tech and at startups to connect ... Gratafy are happy to host events for their peers to meet ...
(Date:9/16/2014)... Treatment with endocrine therapy and radiation therapy as ... of care for women with hormone-receptor positive (HR+) ... at Fox Chase Cancer Center, however, shows that ... populations with the disease. , The results, ... Society for Radiation Oncology,s 56th Annual Meeting on ...
(Date:9/16/2014)... 16, 2014 This year’s theme is ... Sustainable company Glen Mills, Pennsylvania, September 15, 2014- Holganix, ... of the fastest growing companies in the country, produces ... shrub, and tree health-care by naturally decreasing disease and ... Today it announced that it will hold its third ...
Breaking Medicine News(10 mins):Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2
... who don,t metabolize drug well, , FRIDAY, March 12 (HealthDay ... "black box" warning on its label, alerting patients and doctors ... officials said Friday. , Patients with a certain genetic variation ... puts them at risk for heart attack and stroke, the ...
... with a known sex offender is beginning to settle in as a dark, dark corner of the landscape of life. Slowly we are taking up our routines again, changed by ... ... ... ...
... released the following statement.  , ... , , ... ... "We applaud the steps taken by the Congressional Black Caucus and the White House to meet to discuss the ...
... , ... , ... ... ST. LOUIS , March 12 More than 200 Teamsters and religious leaders held a rally and prayer vigil at Ascension ...
... Award Presented to Joel A. Gingras, Jr. Memorial Fund , ... , , ... ... CHICAGO , March 12 The American Brain Tumor Association (ABTA) presented its first ...
... profitable and industry-leading corporation, LIMU, based in Florida , today announced a brand transformation for 2010.   With ... upcoming international convention March 19 – 20, 2010 in Dallas, Texas . , ... ... , ...
Cached Medicine News:Health News:Plavix Less Effective in Some Patients 2Health News:Plavix Less Effective in Some Patients 3Health News:TypeAMom.net on Keeping Daughters Safe From Predators 2Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 2Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 3Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 4Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 5Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 6Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 7Health News:Teamsters, Religious Leaders Call on Ascension Health to Respect Rights of Workers, Patients and Communities 8Health News:American Brain Tumor Association Recognizes Philadelphia Family Foundation With Annual Award 2Health News:American Brain Tumor Association Recognizes Philadelphia Family Foundation With Annual Award 3Health News:LIMU Accelerates Growth Era With Brand Transformation 2Health News:LIMU Accelerates Growth Era With Brand Transformation 3
... The RapidPCP test is an immunochromatography ... It is,designed for qualitative determination of ... cut-off level of 25 ng/mL. This ... the point of care location,and is ...
... Rapid Opiate II Rapid Opiates is an ... is designed for qualitative determination of Opiates ... presence of morphine in human urine above ... This assay has not been evaluated in ...
... All of DOA Panel ... one step in vitro test. ... of drug substances in human ... not,been evaluated in the point ...
... an immunochromatography based one step in vitro ... THC and its metabolites in human urine,specimens. ... urine above a cut-off,level of 50 ng/mL ... been evaluated in the point of care,location ...
Medicine Products: